Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1

Cerebellum

Volumn 12, Issue 1, 2013, Pages 74-82

  Nag, Nupur ^a   Tarlac, Volga ^a   Storey, Elsdon ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cerebellar ataxia; Drug treatment; Motor behaviour; Mouse models; Rotor rod; Translational studies

Indexed keywords

AMANTADINE; BUSPIRONE; RILUZOLE; ZOLPIDEM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEDATION; SPINOCEREBELLAR DEGENERATION; TRANSLATIONAL RESEARCH; TREATMENT DURATION;

AMANTADINE; ANIMALS; BUSPIRONE; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; GENOTYPE; HYPNOTICS AND SEDATIVES; KYPHOSIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PHENOTYPE; PURKINJE CELLS; PYRIDINES; RILUZOLE; SEROTONIN RECEPTOR AGONISTS; SPINOCEREBELLAR ATAXIAS;

EID: 84872498626     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-012-0399-x     Document Type: Article

References (31)

1. Zoghbi HY, Orr HT. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem. 2009;284:7425-9.
2. Zoghbi HY, Orr HT. Spinocerebellar ataxia type 1. Semin Cell Biol. 1995;6:29-35.
3. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 2002;34:905-19.
4. Cerminara NL. Cerebellar modules: individual or composite entities? J Neurosci. 2010;30:16065-7.
5. Schweighofer N, Doya K, Kuroda S. Cerebellar aminergic neuromodulation: towards a functional understanding. Brain Res Brain Res Rev. 2004;44:103-16.
6. Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology. 2010;74:839-45.
7. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005;25:3312-22.
8. Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985;110:357-61.
9. Botez MI, Botez-Marquard T, Elie R, Pedraza OL, Goyette K, Lalonde R. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry. 1996;61:259-64.
10. Filla A, De Michele G, Orefice G, Santorelli F, Trombetta L, Banfi S, et al. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can J Neurol Sci. 1993;20:52-5.
11. Hassin-Baer S, Korczyn AD, Giladi N. An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment. J Neural Transm. 2000;107:1187-9.
12. Kaefer V, Semedo JG, Kahl VFS, Von Borowsky RG, Gianesini J, Kist TBL, et al. DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. J Appl Toxicol. 2010;30:745-53.
13. Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med. 2004;351:511-2.
14. Murphy HM, Ihekoronze C, Wideman CH. Zolpidem-induced changes in activity, metabolism, and anxiety in rats. Pharmacol Biochem Behav. 2011;98:81-6.
15. Elliot EE, White JM. The acute effects of zolpidem compared to diazepam and lorazepam using radiotelemetry. Neuropharmacology. 2001;40:717-21.
16. Fahey J, Grassi J, Reddi J, Greenblatt D. Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses. Pharmacol Biochem Behav. 2006;83:21-7.
17. Trouillas P, Xie J, Adeleine P, Michel D, Vighetto A, Honnorat J, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol. 1997;54:749-52.
18. Assadi M, Campellone JV, Janson CG, Veloski JJ, Schwartzman RJ, Leone P. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci. 2007;260:143-6.
19. Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52:982-8.
20. Holroyd-Leduc JM, Liu BA, Maki BE, Zecevic A, Hermann N, Black SE. The role of buspirone for the treatment of cerebellar ataxia in an older individual. Can J Clin Pharmacol. 2005;12:e218-21.
21. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991;19:4293.
22. Swannick B. MIMS annual. 32nd ed. Sydney: UBM Medica Australia; 2008.
23. Center for Drug Evaluation and Research. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, Maryland, USA: US Food and Drug Administration; 2005. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm078932.pdf
24. Carter RJ, Morton J, Dunnett SB. Motor coordination and balance in rodents. Curr Protoc Neurosci. 2001;8.12.1-8.12.14.
25. Fratkin JD, Vig PJ. Neuropathology of degenerative axtaxias. In: Subramony SH, Durr A, editors. Ataxic disorders: handbook of clinical neurology. Edinburgh: Elsevier; 2012. p. 111-26.
26. Ogawa M, Shigeto H, Yamamoto T, Oya Y, Wada K, Nishikawa T, et al. d-cycloserine for the treatment of ataxia in spinocerebellar degeneration. J Neurol Sci. 2003;210:53-6.
27. Saigoh K, Matsui K, Takahashi K, Nishikawa T, Wada K. The stereo-specific effect of d-serine ethylester and the d-cycloserine in ataxic mutant mice. Brain Res. 1998;808:42-7.
28. Cao Y-J, Dreixler JC, Couey JJ, Houamed KM. Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur J Pharmacol. 2002;449:47-54.
29. Poewe W, Mahlkne CP. Pharmacological treatment of Parkinson's disease. In: Watts RL, Standaert DG, Obeso JA, editors. Movement disorders. New York: McGraw Hill; 2011. p. 277-8.
30. Pogorelov VM, Lanthorn TH, Savelieva KV. Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice. J Neurosci Methods. 2007;162:222-8.
31. Pokk P, Zharkovsky A. The effects of buspirone on the behaviour of control and stressed mice. J Physiol Pharmacol. 1998;49:175-85.